RSS Subscribe to our Nanotechnology Business News feed

Calando Receives FDA Approval for Phase I Clinical Trial Using a Targeted siRNA Nanoparticle Therapeutic

Calando Pharmaceuticals announced that the U.S. Food and Drug Administration has approved its investigational new drug application for lead anti-cancer compound, CALAA-01. The drug candidate is a targeted nanoparticle, comprised of a proprietary, non-chemically-modified siRNA against the M2 subunit of ribonucleotide reductase formulated with Calando?s proprietary RONDEL polymer delivery system.

Apr 22nd, 2008

Read more

Renesas Collaborates With IMEC on Reconfigurable RF Transceivers

Renesas Technology Corp., one of the world's leading semiconductor system solutions providers for mobile, automotive and PC/AV (Audio Visual) markets, has entered into a strategic research collaboration with IMEC, Europe's leading independent research center in the field of nanoelectronics, to perform research on 45nm RF transceivers targeting Gbit/s cognitive radios.

Apr 21st, 2008

Read more